Investigational monoclonal antibody to treat Ebola is safe in adults

(NIH/National Institute of Allergy and Infectious Diseases) The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the NIH Clinical Center in Bethesda, Md. The National Institute of Allergy and Infectious Diseases' Vaccine Research Center developed the investigational treatment and conducted and sponsored the trial. (Source: EurekAlert! - Infectious and Emerging Diseases)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2B4DorI